
SNU-387 was derived in 1990 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Korean patient who had been treated by transcatheter arterial embolization with lipoidol plus a combination of doxorubicin and mitomycin-C. Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat-inactivated fetal bovine serum. After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum.
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use




Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?